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for Met2 were 30.5%, 21.5%, 24.8% and 16.4%. The age-adjusted preva-
lence of Met (Met2) decreased significantly by 12.1% (18.7%) in men and
16.6% (23.7%) in women. Of the five Met criteria, decreasing trends were
observed in the prevalence of high blood pressure, elevated fasting glucose,
low HDL cholesterol. By contrast, prevalence of abdominal obesity appeared
unchanged whereas prevalence of hypertriglyceridemia increased signifi-
cantly.
Conclusions: In France, the prevalence of the metabolic syndrome tended
to decline in the last decade in both genders, particularly in women.
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Purpose: Assessment of cardiovascular risk level is uniformly recom-
mended for appropriate management of risk factors. Risk of all-cause
death is seldom considered in available algorithms. We aimed to establish
an updated algorithm to predict 10-year all-cause mortality in apparently
healthy subjects.
Methods: Our analysis was based on the Third French MONICA Cross-
sectional survey on cardiovascular risk factors (1995-1996). Participants aged
35-64 were randomly recruited from French polling lists. Subjects with a his-
tory of atherosclerotic cardiovascular disease or severe chronic disease were
excluded. Vital status was obtained 10 years after inclusion.
Results: There were 3208 participants and 156 deaths over the 10-year
period. Determinants significantly and independently associated with 10-year
all-cause death were living area (Hazard Ratio=1.04 [95% confidence interval:
0.67-1.61]
 
for East, HR=1.76 [1.21-2.58] for North, versus South-west of
France), age (HR=1.64 [1.02-2.64] for 45-54, HR=3.89 [2.49-6.09] for 55-64
vs 35-44 years), male gender (HR=2.11 [1.48-3.01]), no high school comple-
tion (HR=1.57 [1.05-2.33]), smoking (HR=2.61 [1.45-4.70] for smoking < 15
packs-years
,
 HR=2.90 [2.01-4.17] for ≥ 15 packs-years,
 
vs non-smoking), sys-
tolic blood pressure ≥ 160 mmHg (HR= 1.57 [1.03-2.39]), LDL-cholesterol ≥
5.2 mmol/l (HR=1.62 [1.01-2.61]) and diabetes (HR=1.62 [1.10-2.37]). We
developed an algorithm and established score sheets to estimate absolute 10-
year risk of death, for a given subject, according to baseline characteristics.
For example, a non diabetic, heavy smoker, 46 year old man, living in South-
west of France, who did not complete high school, with LDL-cholesterol ≥ 5.2
mmol/l and systolic blood pressure < 160 mmHg, has a 17% 10-year risk of
death.
Conclusions: This prediction algorithm is a simple tool adapted to a Euro-
pean population to guide practitioners towards a more or less aggressive man-
agement of risk factors in apparently healthy subjects.
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Background: Epidemiological studies are needed to evaluate the impact of
the recent changes in clinical practice on the incidence of cardioembolic stroke
with atrial fibrillation (CE/AF stroke).
Methods: Overall ischemic strokes were prospectively ascertained in the
population-based registry of Dijon, France (150,000 inhabitants), from 1985 to
2006. We evaluated trends in incidence rates, risk factors, prestroke therapy,
and survival in CE/AF stroke.
Results: 3064 ischemic strokes including 572 (18.7%) CE/AF strokes were
recorded. Over the 22 years, a decrease in the incidence of overall CE/AF
stroke was noted ([IRR] 0.9858, 95% CI 0.9731-0.9986; p=0.03). We
observed a higher prevalence of previous AF, previous myocardial infarction,
and patients aged >70 years in CE/AF strokes (p<0.0001) whereas hypercho-
lesterolemia was more prevalent in other ischemic strokes (p=0.003). A signif-
icant increase in the use of anticoagulants and antiplatelet agents was noted,
and was particularly pronounced for CE/AF strokes with previous AF. For CE/
AF strokes, survival rates were 72% at 1 month (95% CI 0.68-0.76), 52% at 1
year (95% CI 0.48-0.56), and 43% (95% CI 0.39-0.48) at 2 years, and
remained lower than those of other ischemic strokes.
Conclusions: The decrease in the incidence of CE/AF stroke may reflect
the increase in the utilization of antithrombotic therapy in patients with AF,
but the use of such therapies will have to increase further because of the
expected ageing of the population in coming years.
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Purpose: Although statins are the cornerstone of cardiovascular (CV) pre-
vention, patients (pts) treated with statins remain at substantial CV risk. Per-
sistent lipid abnormalities, among other CV risk factors (RF), are likely to
contribute to this residual CV risk. The objective of the study was to assess
the prevalence of dyslipidemia in high-risk pts receiving statin therapy.
Methods: This French cross-sectional study was conducted by 741 general
practitioners or specialists within the international DYSIS study performed in
12 countries (Europe, Canada). Pts were ≥45 years-old, on statin therapy for
≥3 months with available lipid values. A clinical examination and the
recording of the latest lipid values on statin were performed. High-risk pts
included pts with CV disease, or pts with diabetes and 2 or more RF or
patients with a 10 years risk of coronary event > 20%.
Results: Among 4335 pts included in DYSIS, 2669 (61.6%) were at high
risk. Data for this group of pts are presented hereafter. Their mean age was
66.9 ± 9.8 years, 72.6% were male, 78.6% had hypertension, 48.2% had dia-
betes, 29.9% had family history of premature CV disease and 13.3% were
smokers. CHD was present in 55.1% of pts, cerebrovascular disease in 12.2%
and peripheral artery disease in 21.7%. 30.5% were obese and 66.7% had met-
abolic syndrome.
Conclusion: Persistent dyslipidemia is still prevalent in high risk statin-
treated pts in France, with high proportions of pts not at LDL-C goal with low
HDL-C and/or elevated triglycerides. An intensive and comprehensive lipid
management in this population would decrease the prevalence of lipid abnor-
malities and might contribute to further decrease the CV risk.
Table. Percentage of high risk statin-treated pts with different lipid abnor-
malities (n=2669) 
 
LDL-C 
not at goal 
(> 1 g/l)
Low HDL-C 
(<0.40 g/l)
Elevated TG 
(>1.5 g/l)
LDL-C 
not at goal 
+ HDL-C 
<0.40 g/l 
and/or 
TG>1.5 g/l
High CV risk 
pts (%)
52.4 23.0 38.2 25.7
